Home World News Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib... World News Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 1007 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR El cáncer en mi comunidad: Superar los retrasos en la atención... July 6, 2023 EMA Recommends Granting a Marketing Authorisation for Camizestrant June 5, 2026 New study supports extending cervical screening intervals for people who test... May 31, 2022 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... December 17, 2021 Load more HOT NEWS Merging the Histologic and Molecular Data Into an Integrated Score Significantly... Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA... Can Acupuncture Help Cancer Survivors with Chronic Pain? Couple Buys Customized SUV To Give Free Rides To Critically Ill...
